Search
During the investor conference call following the release of the financial report, Ziar Mik Doustdar, the incoming CEO of Novo Nordisk, addressed concerns regarding semaglutide competition in the Chinese market. He noted that while sales of GLP-1 diabetes medications in China have experienced a decline, sales of weight loss drugs are steadily on the rise. Doustdar attributed the drop in diabetes drug sales to fluctuations in dealer inventory, explaining that semaglutide for weight loss, which was only approved last year, is currently in a phase of volume expansion and has yet to reach second, third, and fourth-tier cities. He further emphasized that the Chinese market's sales strategy encompasses not only offline pharmacies but also crucial online channels.
-
C114 Communication Network -
Communication Home
